Top

Published in:

01-06-2010 | Brief Report

Severe prolonged cholestatic hepatitis caused by exemestane

Authors: Ting Bao, John Fetting, Laura Mumford, Jane Zorzi, Karineh Shahverdi, Stacie Jeter, Frank Herlong, Vered Stearns, Linda Lee

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Excerpt

Aromatase inhibitors (AIs) are used as first-line adjuvant hormonal therapy in postmenopausal women with hormone receptor-positive breast cancer, either as monotherapy or sequential therapy after tamoxifen [1‐6]. Unlike tamoxifen, the former gold standard adjuvant hormonal therapy, AIs cause musculoskeletal symptoms, osteoporosis, and bone fractures [1‐6]. Although AIs such as letrozole and anastrozole also cause liver enzyme elevation unrelated to liver metastasis in 3–5% patients,¹ ^, ² severe hepatotoxicity has rarely been associated with AIs. We report a case of severe prolonged cholestatic hepatitis caused by exemestane. …

Novartis, Femara (letrozole tablets) package insert, 2004.

AstraZeneca, ARIMIDEX (anastrozole tablets) package insert, 2005.

Pfizer, Aromasin (exemestane tablets) package insert, 2007.

Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139CrossRefPubMed

Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRefPubMed

Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802CrossRefPubMed

Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRefPubMed

Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 23:5138–5147CrossRefPubMed

Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629CrossRefPubMed

Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570CrossRefPubMed

Bohn Sarmiento U, Aguiar Bujanda D, Aguiar Morales J, Rodríguez San Román JL (2003) Toxic hepatitis secondary to oral administration of exemestane. Rev Oncol 5(9):550–551

Zapata E, Zubiaurre L, Bujanda L, Pierola A (2006) Anastrozole-induced hepatotoxicity. Eur J Gastroenterol Hepatol 18:1233–1234CrossRefPubMed

10.

de la Cruz L, Romero-Vazquez J, Jimenez-Saenz M, Padron JR, Herrerias-Gutierrez JM (2007) Severe acute hepatitis in a patient treated with anastrozole. Lancet 369:23–24CrossRefPubMed

11.

Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485CrossRefPubMed

12.

Chalasani N, Fontana RJ, Bonkovsky HL et al. (2008) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 135:1924–1934, 1934 e1–e4

13.

Trauner M, Meier PJ, Boyer JL (1998) Molecular pathogenesis of cholestasis. N Engl J Med 339:1217–1227CrossRefPubMed

14.

Robin MA, Le Roy M, Descatoire V, Pessayre D (1997) Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 26(Suppl 1):23–30CrossRefPubMed

15.

Hautekeete ML, Horsmans Y, Van Waeyenberge C et al (1999) HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117:1181–1186CrossRefPubMed

Title: Severe prolonged cholestatic hepatitis caused by exemestane
Authors: Ting Bao
John Fetting
Laura Mumford
Jane Zorzi
Karineh Shahverdi
Stacie Jeter
Frank Herlong
Vered Stearns
Linda Lee
Publication date: 01-06-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0576-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Impact of multiple caregiving roles on elevated depressed mood in early-stage breast cancer patients and same-age controls

Two-stage case–control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk

High levels of uPA and PAI-1 predict a good response to anthracyclines

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years

Correlation between consanguineous marriages and age-standardized mortality rate due to breast cancer, an ecologic study

Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region

Keynote webinar | Spotlight on antibody–drug conjugates in cancer